For research use only. Not for therapeutic Use.
XPW1 is a potent and selective CDK9 inhibitor with excellent activity against clear cell renal cell carcinoma (ccRCC) and low toxicity[1].
| Catalog Number | I040605 |
| CAS Number | 2700286-66-2 |
| Synonyms | N-[4-[[5-chloro-4-[6-[(3-fluorophenyl)methylamino]pyridin-2-yl]pyridin-2-yl]amino]cyclohexyl]-4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzamide |
| Molecular Formula | C36H39ClFN7O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C36H39ClFN7O2/c1-45(2)19-5-10-35(46)42-28-13-11-25(12-14-28)36(47)43-29-17-15-27(16-18-29)41-34-21-30(31(37)23-40-34)32-8-4-9-33(44-32)39-22-24-6-3-7-26(38)20-24/h3-14,20-21,23,27,29H,15-19,22H2,1-2H3,(H,39,44)(H,40,41)(H,42,46)(H,43,47)/b10-5+ |
| InChIKey | DCNDHFXVQIDEQS-BJMVGYQFSA-N |
| SMILES | CN(C)CC=CC(=O)NC1=CC=C(C=C1)C(=O)NC2CCC(CC2)NC3=NC=C(C(=C3)C4=NC(=CC=C4)NCC5=CC(=CC=C5)F)Cl |
| Reference | [1]. Kuang Z, et al. The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma. Br J Cancer. 2023 Oct 26. |
